Biomoda kurz vorm Ausbruch !!?? - 500 Beiträge pro Seite

[BRBa]

Guten Morgen Mädels und Jungs

Achtung diese Aktie ist nur in USA handelbar
Thread:http://www.wallstreet-online.de/aktien/Biomoda-Aktie

Würde hier ab 0.126$ = BB im Chart einsteigen Alles nur meine persönliche Meinung keine Handelsaufforderung

Gruß BRBa




die MM s sind immer wieder lustig
Recent Trades - Last 10 of 47
Time ET Ex Price Change Volume
15:36:53 Q 0.119 0.0057 550
15:33:12 Q 0.144 0.0307 17,500
15:02:48 Q 0.13 0.0167 6,930
15:02:45 Q 0.13 0.0167 3,000
15:00:11 Q 0.13 0.0167 20,000
14:56:41 Q 0.13 0.0167 3,070
14:56:20 Q 0.125 0.0117 10,000
14:56:18 Q 0.125 0.0117 18,867
14:54:33 Q 0.12 0.0067 11,133
14:22:13 Q 0.12 0.0067 7,100

04.10., 13:55 GLOBAL BIOTECH INVESTING
Biomoda anstehenden Daten zu Cypath rücken immer näher
Endingen (aktiencheck.de AG) - Sobald die Aktie von Biomoda (ISIN US0906271004/ WKN A0MSTL) anspringt, muss man als Anleger dabei sein, raten die Experten von "Global Biotech Investing".
Bei Biomoda würden die anstehenden Daten zu Cypath immer näher rücken. Bei Cypath handle es sich um ein nicht-invasives Testverfahren zur Früherkennung von Lungenkrebs. Es sei der vielversprechendeste Produktkandidat von Biomoda. Sollte die Phase II-Studie erfolgreich verlaufen, würden die Analysten von LifeTech für Ende des Jahres die Aufnahme einer pivotalen Phase III-Studie erwarten
Quelle:http://analysen.onvista.de/empfehlungen/artikel/04.10.2010-1…

Also bis zum 12.11 ist Spannung angesagt
2010-11-08 09:10 ET - News Release



ALBUQUERQUE, N.M. -- (Business Wire)

Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) will present the latest developments on its CyPath® diagnostic assay for the detection of early-stage lung cancer at the LifeTech Capital Miami Medical Investors Conference on Friday, November 12, 2010, in Miami, Florida.

The LifeTech Capital Miami Medical Investors Conference connects promising biotechnology companies and key medical and scientific opinion leaders with institutional and accredited investors from across the country. Biomoda is one of 24 companies presenting at the one-day conference at the JW Marriott Marquis Miami.

“We are pleased to have the opportunity to talk about our molecular marker technology before an audience that understands the healthcare sector. This audience will appreciate the market potential for a non-invasive, inexpensive and accurate screening tool for lung and other cancers,” said Biomoda President and Chief Executive Officer John Cousins.

Biomoda’s CyPath® labeling solution for the early detection of cancers binds to cancer cells and fluoresces under specific frequencies of medium light. Biomoda is seeking Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device. The company is concluding the pilot clinical trial and preparing to launch the pivotal trial. Pending FDA approval, CyPath® is for investigational use only.

About Biomoda

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice.


Contacts:

Biomoda, Inc.

Julie Anne Overton, 505-577-0918

Source: Biomoda, Inc.

Quelle:http://www.stockwatch.com/News/Item.aspx?bid=U-b005227-U:BMO…

[BRBa]

[BRBa]

Quelle:http://www.stockta.com/cgi-bin/analysis.pl?symb=BMOD&num1=17…

[klr]

Fehlt noch etwas das Volumen.....

aber bei Biotechwerten kann das schnell kommen.

Gruß
KLR

[BRBa]

Antwort auf Beitrag Nr.: 40.483.119 von klr am 09.11.10 13:56:12

Da hast wohl auch Recht aber zur Zeit wollen nur wenige verkaufen hier fehlt nur ein kleiner Funke



Quelle:http://www.otcmarkets.com/stock/BMOD/quote

[Alphatier]

Antwort auf Beitrag Nr.: 40.485.592 von BRBa am 09.11.10 17:30:45

Diesen "Funken" gabs schon zweimal in den letzten Jahren.

Aber kuckt Euch doch mal das andere DiskussionsBoard zum Thema Biomoda an.

[BRBa]

Antwort auf Beitrag Nr.: 40.493.105 von Alphatier am 10.11.10 15:30:45

Mal sehen was ab dem 12.11 mit dem Kurs passiert

[BRBa]

Kommt nächste Woche der Ausbruch aus dem Dreieck

[BRBa]

Composite Indicator
Trend Spotter TM Sell

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Sell
20 Day Bollinger Bands Hold

Short Term Indicators Average: 40% - Buy

mehr dazu hier:http://www.tradingday.com/tbs.html?http://quotes.barchart.co…

[Alphatier]

Antwort auf Beitrag Nr.: 40.517.408 von BRBa am 13.11.10 19:14:50

Ich geh mal davon aus, dass die Biomodas jetzt erst mal (endlich nach Jahren !) die Phase-III-Prüfungen durchziehen müssen.

Wenn da nichts kommt, wird sich - denk ich - auch am Kurs nicht mehr viel ändern.

[Kursziel1000]

Biomoda Selects Quintiles to Help Develop More Accurate Automated System for Detecting Early-Stage Lung Cancer
Date : 11/15/2010 @ 9:10AM
Source : Business Wire
Stock : Biomoda, Inc. (BMOD)
Quote : 0.12 -0.01 (-7.69%) @ 9:43AM


Biomoda Selects Quintiles to Help Develop More Accurate Automated System for Detecting Early-Stage Lung Cancer
Biomoda (BB) (OTCBB:BMOD)
Intraday Stock Chart

Today : Monday 15 November 2010
Click Here for more Biomoda (BB) Charts.

Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) has allied with Quintiles Global Central Laboratories (www.quintiles.com) to help refine the automated image recognition system for measuring the photon emission rate and cell morphology of CyPath®-stained cells to detect early stage lung cancer.

“One of the key prerequisites prior to commercialization is a highly accurate, fully automated system for reading the assay with state-of-the-art digital technology,” Biomoda President John Cousins said. “Quintiles is the perfect partner for us as we develop our own expert system of digital cytopathology for cancer cell identification. Their in-house pathology capabilities and expertise in tissue-based testing are second to none.”

“We look forward to harnessing innovative pathology and digital technologies with Biomoda to streamline and improve the selection of cancer patients in the New Health,” said Christopher Ung, Vice President, Strategic Business & Operations, Oncology, Quintiles. “Quintiles is committed to alliances that support advances in personalized medicine and the development of safer, more effective targeted therapies.”

Biomoda’s CyPath® labeling solution for the early detection of cancers binds to cancer cells and fluoresces under specific frequencies of medium light. Biomoda is seeking Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device. Pending FDA approval, CyPath® is for investigational use only.

Under the terms of the agreement, Quintiles will review CyPath®-stained slides and pap-stained slides to analyze the cell matrices and help Biomoda further calibrate the “signature” of cancer and other aberrant cells that have been labeled with the CyPath® solution.

Quintiles develops proprietary and novel biomarker tests for analyzing genes and proteins that affect cancer cell growth and mutation, and performs these assays at labs in the United States, Scotland and China. Quintiles has the largest and now entirely CAP-accredited central laboratory network in the world, with wholly owned facilities in the United States, Europe, South Africa, India, China, Singapore and Japan, and a tightly controlled network of affiliate laboratories in Argentina and Brazil.

About Biomoda

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice.

[BRBa]

Antwort auf Beitrag Nr.: 40.522.035 von Alphatier am 15.11.10 12:46:50

ja sehe ich auch so,also abwarten ist noch Angesagt

[BRBa]

So bin erst mal hier raus da die 0.10$ Marke nicht gehalten hat

[Alphatier]

Antwort auf Beitrag Nr.: 40.668.809 von BRBa am 08.12.10 05:32:44

Da hab ich mit meinen 30 Cent noch richtig Glück gehabt.

Schade, eigentlich ein guter Laden.